Antidepressant Sirolimus Material Sirolimus Powder Sirolimus
Product Description
Product Details
| Product name |
Sirolimus |
| Cas number |
53123-88-9 |
| Appearance |
White powder |
| MF |
C51H79NO13 |
| MW |
914.17186 |
Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and to treat a rare lung disease called lymphangioleiomyomatosis. It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It inhibits activation of T cells and B cells by reducing the production of interleukin-2 (IL-2).
Application&Function
Sirolimus is indicated for the prevention of organ transplant rejection and for the treatment oflymphangioleiomyomatosis
Rapamycin initially was taken as low toxicity antifungal drugs, and was found immunosuppressive in 1977. From 1989, RAPA was as a new drug for the treatment of organ transplantation rejection in trial, and from animal experiments and clinical application effects, it is of good curative effects, low toxicity and no new immunosuppressant nephrotoxicity.
Now rapamycin is frequently as maintaining immunity drug for transplant organs (especially kidney transplant), to slow down the immune rejection of the organ in transplant surgery, however, scientists recently discovered another purpose: it can be used in the treatment of alzheimer's disease (senile dementia).
Medical researchers from University of Chicago combined commercially available rapamycin oral tablets with grapefruit juice in the treatment of melanoma (a kind of malignant tumor disease common in European and American people), which could greatly improve the anticancer effect of other chemotherapy drugs, thereby prolong the survival time of patients.
Specification
Audited Supplier 
){kind=link}
){kind=link}